ISPE 2017 Europe Annual Conference
Lead and Manage Future Operations
3-5 April 2017, Barcelona, Spain

Conference and Respective Track Feedback

Five minute, ten question survey to help us enhance your future ISPE experience.

The responses are anonymous.

Question Title

* 1. How would you rate your level of satisfaction with this ISPE 2017 Europe Annual Conference in the following areas?

	Poor	Fair	Good	Very Good	Excellent
Technical Content	Technical Content Poor	Technical Content Fair	Technical Content Good	Technical Content Very Good	Technical Content Excellent
Opportunity to interact with the speakers	Opportunity to interact with the speakers Poor	Opportunity to interact with the speakers Fair	Opportunity to interact with the speakers Good	Opportunity to interact with the speakers Very Good	Opportunity to interact with the speakers Excellent
Opportunity to interact/network with other delegates	Opportunity to interact/network with other delegates Poor	Opportunity to interact/network with other delegates Fair	Opportunity to interact/network with other delegates Good	Opportunity to interact/network with other delegates Very Good	Opportunity to interact/network with other delegates Excellent
Quality of the venue	Quality of the venue Poor	Quality of the venue Fair	Quality of the venue Good	Quality of the venue Very Good	Quality of the venue Excellent
Location accessibility	Location accessibility Poor	Location accessibility Fair	Location accessibility Good	Location accessibility Very Good	Location accessibility Excellent
Overall experience	Overall experience Poor	Overall experience Fair	Overall experience Good	Overall experience Very Good	Overall experience Excellent

Question Title

* 2. How likely is it that you would recommend the event to a friend or colleague?

Not at all likely

Extremely likely

Question Title

* 3. Why did you register for this ISPE 2017 Europe Annual Conference? Please tick all boxes that apply.

Networking

Education/Topics/Programme

Industry Updates

Regulatory Information

Location

Question Title

* 4. How did you learn about this ISPE 2017 Europe Annual Conference?

Colleague

Mailing/Invitation

Other

Other (please specify)

Question Title

* 5. Please evaluate the relevance and presentation of the
Keynote speakers

	Poor	Fair	Good	Very Good	Excellent
Juan Andres, Global Head Technical Operations (Manufacturing and Supply Chain), Novartis Pharma - Pharma Manufacturing 2025	Juan Andres, Global Head Technical Operations (Manufacturing and Supply Chain), Novartis Pharma - Pharma Manufacturing 2025 Poor	Juan Andres, Global Head Technical Operations (Manufacturing and Supply Chain), Novartis Pharma - Pharma Manufacturing 2025 Fair	Juan Andres, Global Head Technical Operations (Manufacturing and Supply Chain), Novartis Pharma - Pharma Manufacturing 2025 Good	Juan Andres, Global Head Technical Operations (Manufacturing and Supply Chain), Novartis Pharma - Pharma Manufacturing 2025 Very Good	Juan Andres, Global Head Technical Operations (Manufacturing and Supply Chain), Novartis Pharma - Pharma Manufacturing 2025 Excellent
Gert Mølgaard, Senior Consultant, Mølgaard Consulting - The Hot Spot: Aseptic Manufacturing Trends Towards 2025	Gert Mølgaard, Senior Consultant, Mølgaard Consulting - The Hot Spot: Aseptic Manufacturing Trends Towards 2025 Poor	Gert Mølgaard, Senior Consultant, Mølgaard Consulting - The Hot Spot: Aseptic Manufacturing Trends Towards 2025 Fair	Gert Mølgaard, Senior Consultant, Mølgaard Consulting - The Hot Spot: Aseptic Manufacturing Trends Towards 2025 Good	Gert Mølgaard, Senior Consultant, Mølgaard Consulting - The Hot Spot: Aseptic Manufacturing Trends Towards 2025 Very Good	Gert Mølgaard, Senior Consultant, Mølgaard Consulting - The Hot Spot: Aseptic Manufacturing Trends Towards 2025 Excellent
Pierre-Alain Ruffieux, Global Head of Quality and Compliance, Roche - Quality 2025	Pierre-Alain Ruffieux, Global Head of Quality and Compliance, Roche - Quality 2025 Poor	Pierre-Alain Ruffieux, Global Head of Quality and Compliance, Roche - Quality 2025 Fair	Pierre-Alain Ruffieux, Global Head of Quality and Compliance, Roche - Quality 2025 Good	Pierre-Alain Ruffieux, Global Head of Quality and Compliance, Roche - Quality 2025 Very Good	Pierre-Alain Ruffieux, Global Head of Quality and Compliance, Roche - Quality 2025 Excellent
Robert Nass, SVP Quality and Regulatory Management, Merck KGaA - Enabling Future Pharma Manufacturing – Trends From a Supplier Perspective	Robert Nass, SVP Quality and Regulatory Management, Merck KGaA - Enabling Future Pharma Manufacturing – Trends From a Supplier Perspective Poor	Robert Nass, SVP Quality and Regulatory Management, Merck KGaA - Enabling Future Pharma Manufacturing – Trends From a Supplier Perspective Fair	Robert Nass, SVP Quality and Regulatory Management, Merck KGaA - Enabling Future Pharma Manufacturing – Trends From a Supplier Perspective Good	Robert Nass, SVP Quality and Regulatory Management, Merck KGaA - Enabling Future Pharma Manufacturing – Trends From a Supplier Perspective Very Good	Robert Nass, SVP Quality and Regulatory Management, Merck KGaA - Enabling Future Pharma Manufacturing – Trends From a Supplier Perspective Excellent

Question Title

* 6. Please evaluate the relevance and presentation of the speakers of
Track 1: Factories Of The Future

	Poor	Fair	Good	Very Good	Excellent
Matthew Kennedy, Process Engineer AND Dave DiProspero, Associate, Director of Pharmaceutical Process Technology, CRB Consulting Engineers - Continuous Manufacturing in Biotech and OSD - Including ISPE’s New OSD Guideline	Matthew Kennedy, Process Engineer AND Dave DiProspero, Associate, Director of Pharmaceutical Process Technology, CRB Consulting Engineers - Continuous Manufacturing in Biotech and OSD - Including ISPE’s New OSD Guideline Poor	Matthew Kennedy, Process Engineer AND Dave DiProspero, Associate, Director of Pharmaceutical Process Technology, CRB Consulting Engineers - Continuous Manufacturing in Biotech and OSD - Including ISPE’s New OSD Guideline Fair	Matthew Kennedy, Process Engineer AND Dave DiProspero, Associate, Director of Pharmaceutical Process Technology, CRB Consulting Engineers - Continuous Manufacturing in Biotech and OSD - Including ISPE’s New OSD Guideline Good	Matthew Kennedy, Process Engineer AND Dave DiProspero, Associate, Director of Pharmaceutical Process Technology, CRB Consulting Engineers - Continuous Manufacturing in Biotech and OSD - Including ISPE’s New OSD Guideline Very Good	Matthew Kennedy, Process Engineer AND Dave DiProspero, Associate, Director of Pharmaceutical Process Technology, CRB Consulting Engineers - Continuous Manufacturing in Biotech and OSD - Including ISPE’s New OSD Guideline Excellent
Richard Steiner, Sales Manager, APC Pharma, GEA - Continuous Manufacturing Solutions for Oral Solid Dosage Products - GEA Group	Richard Steiner, Sales Manager, APC Pharma, GEA - Continuous Manufacturing Solutions for Oral Solid Dosage Products - GEA Group Poor	Richard Steiner, Sales Manager, APC Pharma, GEA - Continuous Manufacturing Solutions for Oral Solid Dosage Products - GEA Group Fair	Richard Steiner, Sales Manager, APC Pharma, GEA - Continuous Manufacturing Solutions for Oral Solid Dosage Products - GEA Group Good	Richard Steiner, Sales Manager, APC Pharma, GEA - Continuous Manufacturing Solutions for Oral Solid Dosage Products - GEA Group Very Good	Richard Steiner, Sales Manager, APC Pharma, GEA - Continuous Manufacturing Solutions for Oral Solid Dosage Products - GEA Group Excellent
Klaus N Moeller, Head of Business Development, Glatt Air Techniques , Inc. - Technical Solutions for Continuous Manufacturing: Modular Continuous Processing	Klaus N Moeller, Head of Business Development, Glatt Air Techniques , Inc. - Technical Solutions for Continuous Manufacturing: Modular Continuous Processing Poor	Klaus N Moeller, Head of Business Development, Glatt Air Techniques , Inc. - Technical Solutions for Continuous Manufacturing: Modular Continuous Processing Fair	Klaus N Moeller, Head of Business Development, Glatt Air Techniques , Inc. - Technical Solutions for Continuous Manufacturing: Modular Continuous Processing Good	Klaus N Moeller, Head of Business Development, Glatt Air Techniques , Inc. - Technical Solutions for Continuous Manufacturing: Modular Continuous Processing Very Good	Klaus N Moeller, Head of Business Development, Glatt Air Techniques , Inc. - Technical Solutions for Continuous Manufacturing: Modular Continuous Processing Excellent
Marc Michaelis, Pharmacist/Senior Scientist, Hüttlin GmbH, A Bosch Packaging Technology Company - Continuous Manufacturing as an Enabler for Industry 4.0	Marc Michaelis, Pharmacist/Senior Scientist, Hüttlin GmbH, A Bosch Packaging Technology Company - Continuous Manufacturing as an Enabler for Industry 4.0 Poor	Marc Michaelis, Pharmacist/Senior Scientist, Hüttlin GmbH, A Bosch Packaging Technology Company - Continuous Manufacturing as an Enabler for Industry 4.0 Fair	Marc Michaelis, Pharmacist/Senior Scientist, Hüttlin GmbH, A Bosch Packaging Technology Company - Continuous Manufacturing as an Enabler for Industry 4.0 Good	Marc Michaelis, Pharmacist/Senior Scientist, Hüttlin GmbH, A Bosch Packaging Technology Company - Continuous Manufacturing as an Enabler for Industry 4.0 Very Good	Marc Michaelis, Pharmacist/Senior Scientist, Hüttlin GmbH, A Bosch Packaging Technology Company - Continuous Manufacturing as an Enabler for Industry 4.0 Excellent
Stefania Barzanti, Marketing Manager, IMA ACTIVE Division - IMA S.p.A.	Stefania Barzanti, Marketing Manager, IMA ACTIVE Division - IMA S.p.A. Poor	Stefania Barzanti, Marketing Manager, IMA ACTIVE Division - IMA S.p.A. Fair	Stefania Barzanti, Marketing Manager, IMA ACTIVE Division - IMA S.p.A. Good	Stefania Barzanti, Marketing Manager, IMA ACTIVE Division - IMA S.p.A. Very Good	Stefania Barzanti, Marketing Manager, IMA ACTIVE Division - IMA S.p.A. Excellent
Li Jianming, China FDA - 2016 China Drug Inspection Report	Li Jianming, China FDA - 2016 China Drug Inspection Report Poor	Li Jianming, China FDA - 2016 China Drug Inspection Report Fair	Li Jianming, China FDA - 2016 China Drug Inspection Report Good	Li Jianming, China FDA - 2016 China Drug Inspection Report Very Good	Li Jianming, China FDA - 2016 China Drug Inspection Report Excellent
Miriam Monge, Director of Marketing and Process Development, Sartorius Stedim AND Nienke Vriezen, Director Upstream, Synthon Biopharmaceuticals - Smart Design and Implementation of Synthon’s New Single-Use Facility	Miriam Monge, Director of Marketing and Process Development, Sartorius Stedim AND Nienke Vriezen, Director Upstream, Synthon Biopharmaceuticals - Smart Design and Implementation of Synthon’s New Single-Use Facility Poor	Miriam Monge, Director of Marketing and Process Development, Sartorius Stedim AND Nienke Vriezen, Director Upstream, Synthon Biopharmaceuticals - Smart Design and Implementation of Synthon’s New Single-Use Facility Fair	Miriam Monge, Director of Marketing and Process Development, Sartorius Stedim AND Nienke Vriezen, Director Upstream, Synthon Biopharmaceuticals - Smart Design and Implementation of Synthon’s New Single-Use Facility Good	Miriam Monge, Director of Marketing and Process Development, Sartorius Stedim AND Nienke Vriezen, Director Upstream, Synthon Biopharmaceuticals - Smart Design and Implementation of Synthon’s New Single-Use Facility Very Good	Miriam Monge, Director of Marketing and Process Development, Sartorius Stedim AND Nienke Vriezen, Director Upstream, Synthon Biopharmaceuticals - Smart Design and Implementation of Synthon’s New Single-Use Facility Excellent
Laurent Arnould, Senior Manager, Global Sourcing and Third-Party Manufacturing, Abbott AND Michel Raschas, Consulting Validation and Services Director, PROGMP SAS - Serialisation at CMOs in Europe : A Case Study for a Proposal of new ISPE CoP	Laurent Arnould, Senior Manager, Global Sourcing and Third-Party Manufacturing, Abbott AND Michel Raschas, Consulting Validation and Services Director, PROGMP SAS - Serialisation at CMOs in Europe : A Case Study for a Proposal of new ISPE CoP Poor	Laurent Arnould, Senior Manager, Global Sourcing and Third-Party Manufacturing, Abbott AND Michel Raschas, Consulting Validation and Services Director, PROGMP SAS - Serialisation at CMOs in Europe : A Case Study for a Proposal of new ISPE CoP Fair	Laurent Arnould, Senior Manager, Global Sourcing and Third-Party Manufacturing, Abbott AND Michel Raschas, Consulting Validation and Services Director, PROGMP SAS - Serialisation at CMOs in Europe : A Case Study for a Proposal of new ISPE CoP Good	Laurent Arnould, Senior Manager, Global Sourcing and Third-Party Manufacturing, Abbott AND Michel Raschas, Consulting Validation and Services Director, PROGMP SAS - Serialisation at CMOs in Europe : A Case Study for a Proposal of new ISPE CoP Very Good	Laurent Arnould, Senior Manager, Global Sourcing and Third-Party Manufacturing, Abbott AND Michel Raschas, Consulting Validation and Services Director, PROGMP SAS - Serialisation at CMOs in Europe : A Case Study for a Proposal of new ISPE CoP Excellent
Fatma Taman, General Manager, PharmaVision Pharmaceutical - Mass Serialisation Implementation in Turkey	Fatma Taman, General Manager, PharmaVision Pharmaceutical - Mass Serialisation Implementation in Turkey Poor	Fatma Taman, General Manager, PharmaVision Pharmaceutical - Mass Serialisation Implementation in Turkey Fair	Fatma Taman, General Manager, PharmaVision Pharmaceutical - Mass Serialisation Implementation in Turkey Good	Fatma Taman, General Manager, PharmaVision Pharmaceutical - Mass Serialisation Implementation in Turkey Very Good	Fatma Taman, General Manager, PharmaVision Pharmaceutical - Mass Serialisation Implementation in Turkey Excellent
Gert Vleugels, Global Programme Manager Track-and-Trace, Merck KgA - Serialisation - Opportunities and Challenges of Implementation	Gert Vleugels, Global Programme Manager Track-and-Trace, Merck KgA - Serialisation - Opportunities and Challenges of Implementation Poor	Gert Vleugels, Global Programme Manager Track-and-Trace, Merck KgA - Serialisation - Opportunities and Challenges of Implementation Fair	Gert Vleugels, Global Programme Manager Track-and-Trace, Merck KgA - Serialisation - Opportunities and Challenges of Implementation Good	Gert Vleugels, Global Programme Manager Track-and-Trace, Merck KgA - Serialisation - Opportunities and Challenges of Implementation Very Good	Gert Vleugels, Global Programme Manager Track-and-Trace, Merck KgA - Serialisation - Opportunities and Challenges of Implementation Excellent
Marcel de Grutter, Executive Director, Open-SCS - Global Packaging Serialisation	Marcel de Grutter, Executive Director, Open-SCS - Global Packaging Serialisation Poor	Marcel de Grutter, Executive Director, Open-SCS - Global Packaging Serialisation Fair	Marcel de Grutter, Executive Director, Open-SCS - Global Packaging Serialisation Good	Marcel de Grutter, Executive Director, Open-SCS - Global Packaging Serialisation Very Good	Marcel de Grutter, Executive Director, Open-SCS - Global Packaging Serialisation Excellent
Lars Olsen, Global Technology Partner - Assembly and Packaging, NNE Pharmaplan - Serialisation: Global Overview and Trends, EU Delegated Acts: Opportunities and Challenges	Lars Olsen, Global Technology Partner - Assembly and Packaging, NNE Pharmaplan - Serialisation: Global Overview and Trends, EU Delegated Acts: Opportunities and Challenges Poor	Lars Olsen, Global Technology Partner - Assembly and Packaging, NNE Pharmaplan - Serialisation: Global Overview and Trends, EU Delegated Acts: Opportunities and Challenges Fair	Lars Olsen, Global Technology Partner - Assembly and Packaging, NNE Pharmaplan - Serialisation: Global Overview and Trends, EU Delegated Acts: Opportunities and Challenges Good	Lars Olsen, Global Technology Partner - Assembly and Packaging, NNE Pharmaplan - Serialisation: Global Overview and Trends, EU Delegated Acts: Opportunities and Challenges Very Good	Lars Olsen, Global Technology Partner - Assembly and Packaging, NNE Pharmaplan - Serialisation: Global Overview and Trends, EU Delegated Acts: Opportunities and Challenges Excellent
Kavita Ramalingam Iyer, Regulatory Professional, GRACS- Vaccine CMC, Merck Sharp & Dohme Corp. - An Experimental Approach Supporting QRM Evaluations: Enabling Closed Systems In CNC Environment	Kavita Ramalingam Iyer, Regulatory Professional, GRACS- Vaccine CMC, Merck Sharp & Dohme Corp. - An Experimental Approach Supporting QRM Evaluations: Enabling Closed Systems In CNC Environment Poor	Kavita Ramalingam Iyer, Regulatory Professional, GRACS- Vaccine CMC, Merck Sharp & Dohme Corp. - An Experimental Approach Supporting QRM Evaluations: Enabling Closed Systems In CNC Environment Fair	Kavita Ramalingam Iyer, Regulatory Professional, GRACS- Vaccine CMC, Merck Sharp & Dohme Corp. - An Experimental Approach Supporting QRM Evaluations: Enabling Closed Systems In CNC Environment Good	Kavita Ramalingam Iyer, Regulatory Professional, GRACS- Vaccine CMC, Merck Sharp & Dohme Corp. - An Experimental Approach Supporting QRM Evaluations: Enabling Closed Systems In CNC Environment Very Good	Kavita Ramalingam Iyer, Regulatory Professional, GRACS- Vaccine CMC, Merck Sharp & Dohme Corp. - An Experimental Approach Supporting QRM Evaluations: Enabling Closed Systems In CNC Environment Excellent
Eva Urban, Senior Manager, Global Quality Risk Management, Celgene - Integrating Quality Systems With CMOs Within the Manufacturing Network of the Future	Eva Urban, Senior Manager, Global Quality Risk Management, Celgene - Integrating Quality Systems With CMOs Within the Manufacturing Network of the Future Poor	Eva Urban, Senior Manager, Global Quality Risk Management, Celgene - Integrating Quality Systems With CMOs Within the Manufacturing Network of the Future Fair	Eva Urban, Senior Manager, Global Quality Risk Management, Celgene - Integrating Quality Systems With CMOs Within the Manufacturing Network of the Future Good	Eva Urban, Senior Manager, Global Quality Risk Management, Celgene - Integrating Quality Systems With CMOs Within the Manufacturing Network of the Future Very Good	Eva Urban, Senior Manager, Global Quality Risk Management, Celgene - Integrating Quality Systems With CMOs Within the Manufacturing Network of the Future Excellent
Ranj Rihal, Product Expert for ORION Purified Water AND Nick Barton, Product Expert for POLARIS Distillation, Veolia Water Technologies - How To Manage the Perceived Risks Associated With RO-based Systems for Production of WFI	Ranj Rihal, Product Expert for ORION Purified Water AND Nick Barton, Product Expert for POLARIS Distillation, Veolia Water Technologies - How To Manage the Perceived Risks Associated With RO-based Systems for Production of WFI Poor	Ranj Rihal, Product Expert for ORION Purified Water AND Nick Barton, Product Expert for POLARIS Distillation, Veolia Water Technologies - How To Manage the Perceived Risks Associated With RO-based Systems for Production of WFI Fair	Ranj Rihal, Product Expert for ORION Purified Water AND Nick Barton, Product Expert for POLARIS Distillation, Veolia Water Technologies - How To Manage the Perceived Risks Associated With RO-based Systems for Production of WFI Good	Ranj Rihal, Product Expert for ORION Purified Water AND Nick Barton, Product Expert for POLARIS Distillation, Veolia Water Technologies - How To Manage the Perceived Risks Associated With RO-based Systems for Production of WFI Very Good	Ranj Rihal, Product Expert for ORION Purified Water AND Nick Barton, Product Expert for POLARIS Distillation, Veolia Water Technologies - How To Manage the Perceived Risks Associated With RO-based Systems for Production of WFI Excellent
Bob Tribe, Asia Pacific Regulatory Affairs Advisor, ISPE - International Regulatory Convergence – Is Enough Being Done?	Bob Tribe, Asia Pacific Regulatory Affairs Advisor, ISPE - International Regulatory Convergence – Is Enough Being Done? Poor	Bob Tribe, Asia Pacific Regulatory Affairs Advisor, ISPE - International Regulatory Convergence – Is Enough Being Done? Fair	Bob Tribe, Asia Pacific Regulatory Affairs Advisor, ISPE - International Regulatory Convergence – Is Enough Being Done? Good	Bob Tribe, Asia Pacific Regulatory Affairs Advisor, ISPE - International Regulatory Convergence – Is Enough Being Done? Very Good	Bob Tribe, Asia Pacific Regulatory Affairs Advisor, ISPE - International Regulatory Convergence – Is Enough Being Done? Excellent

Question Title

* 7. Please evaluate the relevance and presentation of the speakers of
Track 2: Advanced Aseptic Processing

	Poor	Fair	Good	Very Good	Excellent
Roland Guinet, Senior GMDP expert, RGmp Compliance - The New Annex 1: What We Already Know and Some Possible Modifications	Roland Guinet, Senior GMDP expert, RGmp Compliance - The New Annex 1: What We Already Know and Some Possible Modifications Poor	Roland Guinet, Senior GMDP expert, RGmp Compliance - The New Annex 1: What We Already Know and Some Possible Modifications Fair	Roland Guinet, Senior GMDP expert, RGmp Compliance - The New Annex 1: What We Already Know and Some Possible Modifications Good	Roland Guinet, Senior GMDP expert, RGmp Compliance - The New Annex 1: What We Already Know and Some Possible Modifications Very Good	Roland Guinet, Senior GMDP expert, RGmp Compliance - The New Annex 1: What We Already Know and Some Possible Modifications Excellent
Monika Stieglbauer, Ph.D.-student, University of Tübingen - Small Batches Manufacturing in Hospital Pharmacies	Monika Stieglbauer, Ph.D.-student, University of Tübingen - Small Batches Manufacturing in Hospital Pharmacies Poor	Monika Stieglbauer, Ph.D.-student, University of Tübingen - Small Batches Manufacturing in Hospital Pharmacies Fair	Monika Stieglbauer, Ph.D.-student, University of Tübingen - Small Batches Manufacturing in Hospital Pharmacies Good	Monika Stieglbauer, Ph.D.-student, University of Tübingen - Small Batches Manufacturing in Hospital Pharmacies Very Good	Monika Stieglbauer, Ph.D.-student, University of Tübingen - Small Batches Manufacturing in Hospital Pharmacies Excellent
Patrick Baleriaux, CEO, Aseptic Technologies SA - cGMP Fill-Finish Of Cell - and Gene Therapies With Grade C Background	Patrick Baleriaux, CEO, Aseptic Technologies SA - cGMP Fill-Finish Of Cell - and Gene Therapies With Grade C Background Poor	Patrick Baleriaux, CEO, Aseptic Technologies SA - cGMP Fill-Finish Of Cell - and Gene Therapies With Grade C Background Fair	Patrick Baleriaux, CEO, Aseptic Technologies SA - cGMP Fill-Finish Of Cell - and Gene Therapies With Grade C Background Good	Patrick Baleriaux, CEO, Aseptic Technologies SA - cGMP Fill-Finish Of Cell - and Gene Therapies With Grade C Background Very Good	Patrick Baleriaux, CEO, Aseptic Technologies SA - cGMP Fill-Finish Of Cell - and Gene Therapies With Grade C Background Excellent
Elaine Strong, Lead Pharma Solutions, Piramal Healthcare UK Ltd. - Containment in ADC Manufacturing	Elaine Strong, Lead Pharma Solutions, Piramal Healthcare UK Ltd. - Containment in ADC Manufacturing Poor	Elaine Strong, Lead Pharma Solutions, Piramal Healthcare UK Ltd. - Containment in ADC Manufacturing Fair	Elaine Strong, Lead Pharma Solutions, Piramal Healthcare UK Ltd. - Containment in ADC Manufacturing Good	Elaine Strong, Lead Pharma Solutions, Piramal Healthcare UK Ltd. - Containment in ADC Manufacturing Very Good	Elaine Strong, Lead Pharma Solutions, Piramal Healthcare UK Ltd. - Containment in ADC Manufacturing Excellent
Lothar Germeroth, SVP, Juno Therapeutics, Inc. - Cell - and Gene Therapy	Lothar Germeroth, SVP, Juno Therapeutics, Inc. - Cell - and Gene Therapy Poor	Lothar Germeroth, SVP, Juno Therapeutics, Inc. - Cell - and Gene Therapy Fair	Lothar Germeroth, SVP, Juno Therapeutics, Inc. - Cell - and Gene Therapy Good	Lothar Germeroth, SVP, Juno Therapeutics, Inc. - Cell - and Gene Therapy Very Good	Lothar Germeroth, SVP, Juno Therapeutics, Inc. - Cell - and Gene Therapy Excellent
Michael Dieterle, Director, Boehringer Ingelheim AND Jan Schäfer, Manager Process Engineering, Sartorius Stedim Systems GmbH - Boehringer Ingelheim 2000L Commercial Manufacturing in Single-Use	Michael Dieterle, Director, Boehringer Ingelheim AND Jan Schäfer, Manager Process Engineering, Sartorius Stedim Systems GmbH - Boehringer Ingelheim 2000L Commercial Manufacturing in Single-Use Poor	Michael Dieterle, Director, Boehringer Ingelheim AND Jan Schäfer, Manager Process Engineering, Sartorius Stedim Systems GmbH - Boehringer Ingelheim 2000L Commercial Manufacturing in Single-Use Fair	Michael Dieterle, Director, Boehringer Ingelheim AND Jan Schäfer, Manager Process Engineering, Sartorius Stedim Systems GmbH - Boehringer Ingelheim 2000L Commercial Manufacturing in Single-Use Good	Michael Dieterle, Director, Boehringer Ingelheim AND Jan Schäfer, Manager Process Engineering, Sartorius Stedim Systems GmbH - Boehringer Ingelheim 2000L Commercial Manufacturing in Single-Use Very Good	Michael Dieterle, Director, Boehringer Ingelheim AND Jan Schäfer, Manager Process Engineering, Sartorius Stedim Systems GmbH - Boehringer Ingelheim 2000L Commercial Manufacturing in Single-Use Excellent
Markus Keller, Research Engineer and Biologist, Fraunhofer Institute for Manufacturing Engineering and Automation IPA - Cleanroom Suitability Qualification Af a Six-Axis Robot System	Markus Keller, Research Engineer and Biologist, Fraunhofer Institute for Manufacturing Engineering and Automation IPA - Cleanroom Suitability Qualification Af a Six-Axis Robot System Poor	Markus Keller, Research Engineer and Biologist, Fraunhofer Institute for Manufacturing Engineering and Automation IPA - Cleanroom Suitability Qualification Af a Six-Axis Robot System Fair	Markus Keller, Research Engineer and Biologist, Fraunhofer Institute for Manufacturing Engineering and Automation IPA - Cleanroom Suitability Qualification Af a Six-Axis Robot System Good	Markus Keller, Research Engineer and Biologist, Fraunhofer Institute for Manufacturing Engineering and Automation IPA - Cleanroom Suitability Qualification Af a Six-Axis Robot System Very Good	Markus Keller, Research Engineer and Biologist, Fraunhofer Institute for Manufacturing Engineering and Automation IPA - Cleanroom Suitability Qualification Af a Six-Axis Robot System Excellent
Ruben Rizzo, International Sales Manager Projects, SKAN - Isolator Technology VHP Fast Cycles	Ruben Rizzo, International Sales Manager Projects, SKAN - Isolator Technology VHP Fast Cycles Poor	Ruben Rizzo, International Sales Manager Projects, SKAN - Isolator Technology VHP Fast Cycles Fair	Ruben Rizzo, International Sales Manager Projects, SKAN - Isolator Technology VHP Fast Cycles Good	Ruben Rizzo, International Sales Manager Projects, SKAN - Isolator Technology VHP Fast Cycles Very Good	Ruben Rizzo, International Sales Manager Projects, SKAN - Isolator Technology VHP Fast Cycles Excellent
Jean-Pascal Zambaux, President and CEO, Disposable-Lab - Disposable Isolator For Small ATMP Products	Jean-Pascal Zambaux, President and CEO, Disposable-Lab - Disposable Isolator For Small ATMP Products Poor	Jean-Pascal Zambaux, President and CEO, Disposable-Lab - Disposable Isolator For Small ATMP Products Fair	Jean-Pascal Zambaux, President and CEO, Disposable-Lab - Disposable Isolator For Small ATMP Products Good	Jean-Pascal Zambaux, President and CEO, Disposable-Lab - Disposable Isolator For Small ATMP Products Very Good	Jean-Pascal Zambaux, President and CEO, Disposable-Lab - Disposable Isolator For Small ATMP Products Excellent
Niels Guldager, Global Technology Partner, Biotech, NNE Pharmaplan - Is The Biotech Facility of The Future Located In China? Learnings From 15 Flexibile Facility Biotech Projects (2012-2017)	Niels Guldager, Global Technology Partner, Biotech, NNE Pharmaplan - Is The Biotech Facility of The Future Located In China? Learnings From 15 Flexibile Facility Biotech Projects (2012-2017) Poor	Niels Guldager, Global Technology Partner, Biotech, NNE Pharmaplan - Is The Biotech Facility of The Future Located In China? Learnings From 15 Flexibile Facility Biotech Projects (2012-2017) Fair	Niels Guldager, Global Technology Partner, Biotech, NNE Pharmaplan - Is The Biotech Facility of The Future Located In China? Learnings From 15 Flexibile Facility Biotech Projects (2012-2017) Good	Niels Guldager, Global Technology Partner, Biotech, NNE Pharmaplan - Is The Biotech Facility of The Future Located In China? Learnings From 15 Flexibile Facility Biotech Projects (2012-2017) Very Good	Niels Guldager, Global Technology Partner, Biotech, NNE Pharmaplan - Is The Biotech Facility of The Future Located In China? Learnings From 15 Flexibile Facility Biotech Projects (2012-2017) Excellent

Question Title

* 8. Please evaluate the relevance and presentation of the speakers of
Track 3: Clinical and ATMP Supply Chain

	Poor	Fair	Good	Very Good	Excellent
Colin Terry, Partner, Deloitte - Trends In Development of Pharmaceutical Pipelines; Challenges For Pharma Companies and The Clinical Supply Chain	Colin Terry, Partner, Deloitte - Trends In Development of Pharmaceutical Pipelines; Challenges For Pharma Companies and The Clinical Supply Chain Poor	Colin Terry, Partner, Deloitte - Trends In Development of Pharmaceutical Pipelines; Challenges For Pharma Companies and The Clinical Supply Chain Fair	Colin Terry, Partner, Deloitte - Trends In Development of Pharmaceutical Pipelines; Challenges For Pharma Companies and The Clinical Supply Chain Good	Colin Terry, Partner, Deloitte - Trends In Development of Pharmaceutical Pipelines; Challenges For Pharma Companies and The Clinical Supply Chain Very Good	Colin Terry, Partner, Deloitte - Trends In Development of Pharmaceutical Pipelines; Challenges For Pharma Companies and The Clinical Supply Chain Excellent
Alain Frix, CT Supply Chain Design and Management, Eli Lilly - Faster Selection, Termination Of Drug Candidates In Early Development Phase	Alain Frix, CT Supply Chain Design and Management, Eli Lilly - Faster Selection, Termination Of Drug Candidates In Early Development Phase Poor	Alain Frix, CT Supply Chain Design and Management, Eli Lilly - Faster Selection, Termination Of Drug Candidates In Early Development Phase Fair	Alain Frix, CT Supply Chain Design and Management, Eli Lilly - Faster Selection, Termination Of Drug Candidates In Early Development Phase Good	Alain Frix, CT Supply Chain Design and Management, Eli Lilly - Faster Selection, Termination Of Drug Candidates In Early Development Phase Very Good	Alain Frix, CT Supply Chain Design and Management, Eli Lilly - Faster Selection, Termination Of Drug Candidates In Early Development Phase Excellent
Didier Hallard, Senior Consultant R&D, XENDO - Gene Therapy Products In Clinical Trials: The Impact Of Dealing With a Genetically Modified Organism	Didier Hallard, Senior Consultant R&D, XENDO - Gene Therapy Products In Clinical Trials: The Impact Of Dealing With a Genetically Modified Organism Poor	Didier Hallard, Senior Consultant R&D, XENDO - Gene Therapy Products In Clinical Trials: The Impact Of Dealing With a Genetically Modified Organism Fair	Didier Hallard, Senior Consultant R&D, XENDO - Gene Therapy Products In Clinical Trials: The Impact Of Dealing With a Genetically Modified Organism Good	Didier Hallard, Senior Consultant R&D, XENDO - Gene Therapy Products In Clinical Trials: The Impact Of Dealing With a Genetically Modified Organism Very Good	Didier Hallard, Senior Consultant R&D, XENDO - Gene Therapy Products In Clinical Trials: The Impact Of Dealing With a Genetically Modified Organism Excellent
Andrea Zobel, Global Senior Director Portfolio Management, Parexel - Regulatory, Clinical and Logistics Challenges Of ATMPs In Clinical Research	Andrea Zobel, Global Senior Director Portfolio Management, Parexel - Regulatory, Clinical and Logistics Challenges Of ATMPs In Clinical Research Poor	Andrea Zobel, Global Senior Director Portfolio Management, Parexel - Regulatory, Clinical and Logistics Challenges Of ATMPs In Clinical Research Fair	Andrea Zobel, Global Senior Director Portfolio Management, Parexel - Regulatory, Clinical and Logistics Challenges Of ATMPs In Clinical Research Good	Andrea Zobel, Global Senior Director Portfolio Management, Parexel - Regulatory, Clinical and Logistics Challenges Of ATMPs In Clinical Research Very Good	Andrea Zobel, Global Senior Director Portfolio Management, Parexel - Regulatory, Clinical and Logistics Challenges Of ATMPs In Clinical Research Excellent
Heldin Lee-Höhener, Hoffmann-La Roche AG - Breakthrough Therapies - Case Study	Heldin Lee-Höhener, Hoffmann-La Roche AG - Breakthrough Therapies - Case Study Poor	Heldin Lee-Höhener, Hoffmann-La Roche AG - Breakthrough Therapies - Case Study Fair	Heldin Lee-Höhener, Hoffmann-La Roche AG - Breakthrough Therapies - Case Study Good	Heldin Lee-Höhener, Hoffmann-La Roche AG - Breakthrough Therapies - Case Study Very Good	Heldin Lee-Höhener, Hoffmann-La Roche AG - Breakthrough Therapies - Case Study Excellent
Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN	Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN Poor	Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN Fair	Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN Good	Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN Very Good	Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN Excellent
Verónica Torres-Barthelemy, Clinical Supply Management, Bayer - A Climate-Based Approach For IMPs Distribution	Verónica Torres-Barthelemy, Clinical Supply Management, Bayer - A Climate-Based Approach For IMPs Distribution Poor	Verónica Torres-Barthelemy, Clinical Supply Management, Bayer - A Climate-Based Approach For IMPs Distribution Fair	Verónica Torres-Barthelemy, Clinical Supply Management, Bayer - A Climate-Based Approach For IMPs Distribution Good	Verónica Torres-Barthelemy, Clinical Supply Management, Bayer - A Climate-Based Approach For IMPs Distribution Very Good	Verónica Torres-Barthelemy, Clinical Supply Management, Bayer - A Climate-Based Approach For IMPs Distribution Excellent
Ewald Kamp, Head Clinical Distribution and Supply Service, Hoffmann-La Roche AG - Risk-based Shipping – Some Roche Examples	Ewald Kamp, Head Clinical Distribution and Supply Service, Hoffmann-La Roche AG - Risk-based Shipping – Some Roche Examples Poor	Ewald Kamp, Head Clinical Distribution and Supply Service, Hoffmann-La Roche AG - Risk-based Shipping – Some Roche Examples Fair	Ewald Kamp, Head Clinical Distribution and Supply Service, Hoffmann-La Roche AG - Risk-based Shipping – Some Roche Examples Good	Ewald Kamp, Head Clinical Distribution and Supply Service, Hoffmann-La Roche AG - Risk-based Shipping – Some Roche Examples Very Good	Ewald Kamp, Head Clinical Distribution and Supply Service, Hoffmann-La Roche AG - Risk-based Shipping – Some Roche Examples Excellent
Marc Sotty, Clinical Supply Chain Operations – Distribution Head, Sanofi - Direct-To-Patient: A Sanofi Story	Marc Sotty, Clinical Supply Chain Operations – Distribution Head, Sanofi - Direct-To-Patient: A Sanofi Story Poor	Marc Sotty, Clinical Supply Chain Operations – Distribution Head, Sanofi - Direct-To-Patient: A Sanofi Story Fair	Marc Sotty, Clinical Supply Chain Operations – Distribution Head, Sanofi - Direct-To-Patient: A Sanofi Story Good	Marc Sotty, Clinical Supply Chain Operations – Distribution Head, Sanofi - Direct-To-Patient: A Sanofi Story Very Good	Marc Sotty, Clinical Supply Chain Operations – Distribution Head, Sanofi - Direct-To-Patient: A Sanofi Story Excellent
Ruediger Lomb, Global Director Quality & Technical Compliance, World Courier AND Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN - Workshop: Striking The Balance - Application of Risk Management for IMP Distribution	Ruediger Lomb, Global Director Quality & Technical Compliance, World Courier AND Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN - Workshop: Striking The Balance - Application of Risk Management for IMP Distribution Poor	Ruediger Lomb, Global Director Quality & Technical Compliance, World Courier AND Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN - Workshop: Striking The Balance - Application of Risk Management for IMP Distribution Fair	Ruediger Lomb, Global Director Quality & Technical Compliance, World Courier AND Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN - Workshop: Striking The Balance - Application of Risk Management for IMP Distribution Good	Ruediger Lomb, Global Director Quality & Technical Compliance, World Courier AND Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN - Workshop: Striking The Balance - Application of Risk Management for IMP Distribution Very Good	Ruediger Lomb, Global Director Quality & Technical Compliance, World Courier AND Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, MARKEN - Workshop: Striking The Balance - Application of Risk Management for IMP Distribution Excellent
Joana Claverol, CTO Paediatric Clinical trials Unit Manager, FSJD - Empowering Young Patients and Families To Contribute To Peadiatric Clinical Research	Joana Claverol, CTO Paediatric Clinical trials Unit Manager, FSJD - Empowering Young Patients and Families To Contribute To Peadiatric Clinical Research Poor	Joana Claverol, CTO Paediatric Clinical trials Unit Manager, FSJD - Empowering Young Patients and Families To Contribute To Peadiatric Clinical Research Fair	Joana Claverol, CTO Paediatric Clinical trials Unit Manager, FSJD - Empowering Young Patients and Families To Contribute To Peadiatric Clinical Research Good	Joana Claverol, CTO Paediatric Clinical trials Unit Manager, FSJD - Empowering Young Patients and Families To Contribute To Peadiatric Clinical Research Very Good	Joana Claverol, CTO Paediatric Clinical trials Unit Manager, FSJD - Empowering Young Patients and Families To Contribute To Peadiatric Clinical Research Excellent
David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - What is Innovation for Authorities?	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - What is Innovation for Authorities? Poor	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - What is Innovation for Authorities? Fair	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - What is Innovation for Authorities? Good	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - What is Innovation for Authorities? Very Good	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - What is Innovation for Authorities? Excellent
Shailesh Patel, Global Director Technology Strategy, Customer Integration, Catalent Pharma Solutions - What Technological Solutions Exist To Support The Clinical Supply Chain Tomorrow?	Shailesh Patel, Global Director Technology Strategy, Customer Integration, Catalent Pharma Solutions - What Technological Solutions Exist To Support The Clinical Supply Chain Tomorrow? Poor	Shailesh Patel, Global Director Technology Strategy, Customer Integration, Catalent Pharma Solutions - What Technological Solutions Exist To Support The Clinical Supply Chain Tomorrow? Fair	Shailesh Patel, Global Director Technology Strategy, Customer Integration, Catalent Pharma Solutions - What Technological Solutions Exist To Support The Clinical Supply Chain Tomorrow? Good	Shailesh Patel, Global Director Technology Strategy, Customer Integration, Catalent Pharma Solutions - What Technological Solutions Exist To Support The Clinical Supply Chain Tomorrow? Very Good	Shailesh Patel, Global Director Technology Strategy, Customer Integration, Catalent Pharma Solutions - What Technological Solutions Exist To Support The Clinical Supply Chain Tomorrow? Excellent
Sharon Kostishion, Global Clinical Supply Regional Lead, Merck & Co., Inc. - Workshop Topic: Patient Centricity - – Where Are We Going and How Are We Getting There?	Sharon Kostishion, Global Clinical Supply Regional Lead, Merck & Co., Inc. - Workshop Topic: Patient Centricity - – Where Are We Going and How Are We Getting There? Poor	Sharon Kostishion, Global Clinical Supply Regional Lead, Merck & Co., Inc. - Workshop Topic: Patient Centricity - – Where Are We Going and How Are We Getting There? Fair	Sharon Kostishion, Global Clinical Supply Regional Lead, Merck & Co., Inc. - Workshop Topic: Patient Centricity - – Where Are We Going and How Are We Getting There? Good	Sharon Kostishion, Global Clinical Supply Regional Lead, Merck & Co., Inc. - Workshop Topic: Patient Centricity - – Where Are We Going and How Are We Getting There? Very Good	Sharon Kostishion, Global Clinical Supply Regional Lead, Merck & Co., Inc. - Workshop Topic: Patient Centricity - – Where Are We Going and How Are We Getting There? Excellent

Question Title

* 9. Please evaluate the relevance and presentation of the speakers of
Track 4: Data Integrity and GAMP®

	Poor	Fair	Good	Very Good	Excellent
Sion Wyn, Owner, CONFORMITY - Introducing the New GAMP Data Integrity Guide	Sion Wyn, Owner, CONFORMITY - Introducing the New GAMP Data Integrity Guide Poor	Sion Wyn, Owner, CONFORMITY - Introducing the New GAMP Data Integrity Guide Fair	Sion Wyn, Owner, CONFORMITY - Introducing the New GAMP Data Integrity Guide Good	Sion Wyn, Owner, CONFORMITY - Introducing the New GAMP Data Integrity Guide Very Good	Sion Wyn, Owner, CONFORMITY - Introducing the New GAMP Data Integrity Guide Excellent
David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - Data Integrity, the Challenges to Meeting Regulatory Requirement	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - Data Integrity, the Challenges to Meeting Regulatory Requirement Poor	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - Data Integrity, the Challenges to Meeting Regulatory Requirement Fair	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - Data Integrity, the Challenges to Meeting Regulatory Requirement Good	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - Data Integrity, the Challenges to Meeting Regulatory Requirement Very Good	David Churchward, Expert GMDP Inspector at Medicines and Healthcare Products Regulatory Agency, MHRA - Data Integrity, the Challenges to Meeting Regulatory Requirement Excellent
Valeria Frigerio-Regazzoni, Deputy Vice-President Quality Auditing and Compiance, Merck Serono - Quick Wins for Data Integrity Compliance: GAP Assessment and Solving Case Study	Valeria Frigerio-Regazzoni, Deputy Vice-President Quality Auditing and Compiance, Merck Serono - Quick Wins for Data Integrity Compliance: GAP Assessment and Solving Case Study Poor	Valeria Frigerio-Regazzoni, Deputy Vice-President Quality Auditing and Compiance, Merck Serono - Quick Wins for Data Integrity Compliance: GAP Assessment and Solving Case Study Fair	Valeria Frigerio-Regazzoni, Deputy Vice-President Quality Auditing and Compiance, Merck Serono - Quick Wins for Data Integrity Compliance: GAP Assessment and Solving Case Study Good	Valeria Frigerio-Regazzoni, Deputy Vice-President Quality Auditing and Compiance, Merck Serono - Quick Wins for Data Integrity Compliance: GAP Assessment and Solving Case Study Very Good	Valeria Frigerio-Regazzoni, Deputy Vice-President Quality Auditing and Compiance, Merck Serono - Quick Wins for Data Integrity Compliance: GAP Assessment and Solving Case Study Excellent
Brian Duncan, Vice President, Engagement Operations, Quality Executive Partners Inc. - Investigating Potential Data Integrity Incidents, Methods and Tools	Brian Duncan, Vice President, Engagement Operations, Quality Executive Partners Inc. - Investigating Potential Data Integrity Incidents, Methods and Tools Poor	Brian Duncan, Vice President, Engagement Operations, Quality Executive Partners Inc. - Investigating Potential Data Integrity Incidents, Methods and Tools Fair	Brian Duncan, Vice President, Engagement Operations, Quality Executive Partners Inc. - Investigating Potential Data Integrity Incidents, Methods and Tools Good	Brian Duncan, Vice President, Engagement Operations, Quality Executive Partners Inc. - Investigating Potential Data Integrity Incidents, Methods and Tools Very Good	Brian Duncan, Vice President, Engagement Operations, Quality Executive Partners Inc. - Investigating Potential Data Integrity Incidents, Methods and Tools Excellent
Christian Wölbeling, Senior Director, Werum - MES: The Data Integrity Engine For Production Control Strategy Execution	Christian Wölbeling, Senior Director, Werum - MES: The Data Integrity Engine For Production Control Strategy Execution Poor	Christian Wölbeling, Senior Director, Werum - MES: The Data Integrity Engine For Production Control Strategy Execution Fair	Christian Wölbeling, Senior Director, Werum - MES: The Data Integrity Engine For Production Control Strategy Execution Good	Christian Wölbeling, Senior Director, Werum - MES: The Data Integrity Engine For Production Control Strategy Execution Very Good	Christian Wölbeling, Senior Director, Werum - MES: The Data Integrity Engine For Production Control Strategy Execution Excellent
Chris Clark, Director and Principal Consultant, TenTenTen Consulting - Identifying and Controlling Risks To The Integrity of Records and Data	Chris Clark, Director and Principal Consultant, TenTenTen Consulting - Identifying and Controlling Risks To The Integrity of Records and Data Poor	Chris Clark, Director and Principal Consultant, TenTenTen Consulting - Identifying and Controlling Risks To The Integrity of Records and Data Fair	Chris Clark, Director and Principal Consultant, TenTenTen Consulting - Identifying and Controlling Risks To The Integrity of Records and Data Good	Chris Clark, Director and Principal Consultant, TenTenTen Consulting - Identifying and Controlling Risks To The Integrity of Records and Data Very Good	Chris Clark, Director and Principal Consultant, TenTenTen Consulting - Identifying and Controlling Risks To The Integrity of Records and Data Excellent
Paige Kane, Researcher, Dublin Institute of Technology (DIT) - Knowledge Management: A Key To Data Integrity	Paige Kane, Researcher, Dublin Institute of Technology (DIT) - Knowledge Management: A Key To Data Integrity Poor	Paige Kane, Researcher, Dublin Institute of Technology (DIT) - Knowledge Management: A Key To Data Integrity Fair	Paige Kane, Researcher, Dublin Institute of Technology (DIT) - Knowledge Management: A Key To Data Integrity Good	Paige Kane, Researcher, Dublin Institute of Technology (DIT) - Knowledge Management: A Key To Data Integrity Very Good	Paige Kane, Researcher, Dublin Institute of Technology (DIT) - Knowledge Management: A Key To Data Integrity Excellent
Mike Rutherford, Consultant, Laboratory & Quality Systems, Eli Lilly - GAMP Data Integrity Guide: Managing Data Throughout The Data Lifecycle	Mike Rutherford, Consultant, Laboratory & Quality Systems, Eli Lilly - GAMP Data Integrity Guide: Managing Data Throughout The Data Lifecycle Poor	Mike Rutherford, Consultant, Laboratory & Quality Systems, Eli Lilly - GAMP Data Integrity Guide: Managing Data Throughout The Data Lifecycle Fair	Mike Rutherford, Consultant, Laboratory & Quality Systems, Eli Lilly - GAMP Data Integrity Guide: Managing Data Throughout The Data Lifecycle Good	Mike Rutherford, Consultant, Laboratory & Quality Systems, Eli Lilly - GAMP Data Integrity Guide: Managing Data Throughout The Data Lifecycle Very Good	Mike Rutherford, Consultant, Laboratory & Quality Systems, Eli Lilly - GAMP Data Integrity Guide: Managing Data Throughout The Data Lifecycle Excellent
Marina Mangold, Clinical Research Professional, Esculape - Ensuring Data Integrity In Clinical Trials	Marina Mangold, Clinical Research Professional, Esculape - Ensuring Data Integrity In Clinical Trials Poor	Marina Mangold, Clinical Research Professional, Esculape - Ensuring Data Integrity In Clinical Trials Fair	Marina Mangold, Clinical Research Professional, Esculape - Ensuring Data Integrity In Clinical Trials Good	Marina Mangold, Clinical Research Professional, Esculape - Ensuring Data Integrity In Clinical Trials Very Good	Marina Mangold, Clinical Research Professional, Esculape - Ensuring Data Integrity In Clinical Trials Excellent
Anders Vidstrup, Senior IT Quality SME, NNIT - Implementation Of Cloud Solution At Supplier Site and Data Integrity Controls	Anders Vidstrup, Senior IT Quality SME, NNIT - Implementation Of Cloud Solution At Supplier Site and Data Integrity Controls Poor	Anders Vidstrup, Senior IT Quality SME, NNIT - Implementation Of Cloud Solution At Supplier Site and Data Integrity Controls Fair	Anders Vidstrup, Senior IT Quality SME, NNIT - Implementation Of Cloud Solution At Supplier Site and Data Integrity Controls Good	Anders Vidstrup, Senior IT Quality SME, NNIT - Implementation Of Cloud Solution At Supplier Site and Data Integrity Controls Very Good	Anders Vidstrup, Senior IT Quality SME, NNIT - Implementation Of Cloud Solution At Supplier Site and Data Integrity Controls Excellent
Ian Thrussell, Expert Inspector, Recently Retired from WHO - WHO Data Integrity Guidance	Ian Thrussell, Expert Inspector, Recently Retired from WHO - WHO Data Integrity Guidance Poor	Ian Thrussell, Expert Inspector, Recently Retired from WHO - WHO Data Integrity Guidance Fair	Ian Thrussell, Expert Inspector, Recently Retired from WHO - WHO Data Integrity Guidance Good	Ian Thrussell, Expert Inspector, Recently Retired from WHO - WHO Data Integrity Guidance Very Good	Ian Thrussell, Expert Inspector, Recently Retired from WHO - WHO Data Integrity Guidance Excellent
Nuala Calnan, Regulatory Science Researcher, Author and Consultant, Dublin Institute of Technology - Address Human Factors of Data Integrity	Nuala Calnan, Regulatory Science Researcher, Author and Consultant, Dublin Institute of Technology - Address Human Factors of Data Integrity Poor	Nuala Calnan, Regulatory Science Researcher, Author and Consultant, Dublin Institute of Technology - Address Human Factors of Data Integrity Fair	Nuala Calnan, Regulatory Science Researcher, Author and Consultant, Dublin Institute of Technology - Address Human Factors of Data Integrity Good	Nuala Calnan, Regulatory Science Researcher, Author and Consultant, Dublin Institute of Technology - Address Human Factors of Data Integrity Very Good	Nuala Calnan, Regulatory Science Researcher, Author and Consultant, Dublin Institute of Technology - Address Human Factors of Data Integrity Excellent
Jean-Marc Jehl, QA CSV, CSQ & IT specialist, Eli Lilly and Company - Managing Data Integrity in a GMP Environment/Data Integrity Within the Manufacturing Area	Jean-Marc Jehl, QA CSV, CSQ & IT specialist, Eli Lilly and Company - Managing Data Integrity in a GMP Environment/Data Integrity Within the Manufacturing Area Poor	Jean-Marc Jehl, QA CSV, CSQ & IT specialist, Eli Lilly and Company - Managing Data Integrity in a GMP Environment/Data Integrity Within the Manufacturing Area Fair	Jean-Marc Jehl, QA CSV, CSQ & IT specialist, Eli Lilly and Company - Managing Data Integrity in a GMP Environment/Data Integrity Within the Manufacturing Area Good	Jean-Marc Jehl, QA CSV, CSQ & IT specialist, Eli Lilly and Company - Managing Data Integrity in a GMP Environment/Data Integrity Within the Manufacturing Area Very Good	Jean-Marc Jehl, QA CSV, CSQ & IT specialist, Eli Lilly and Company - Managing Data Integrity in a GMP Environment/Data Integrity Within the Manufacturing Area Excellent
Mark Newton, Associate Senior Quality Assurance Consultant, Eli Lilly - Detecting Data Integrity Issues with Analytics	Mark Newton, Associate Senior Quality Assurance Consultant, Eli Lilly - Detecting Data Integrity Issues with Analytics Poor	Mark Newton, Associate Senior Quality Assurance Consultant, Eli Lilly - Detecting Data Integrity Issues with Analytics Fair	Mark Newton, Associate Senior Quality Assurance Consultant, Eli Lilly - Detecting Data Integrity Issues with Analytics Good	Mark Newton, Associate Senior Quality Assurance Consultant, Eli Lilly - Detecting Data Integrity Issues with Analytics Very Good	Mark Newton, Associate Senior Quality Assurance Consultant, Eli Lilly - Detecting Data Integrity Issues with Analytics Excellent

Question Title

* 10. Please evaluate the relevance and experience of the plant tours

	Poor	Fair	Good	Very Good	Excellent
Grifols Plant	Grifols Plant Poor	Grifols Plant Fair	Grifols Plant Good	Grifols Plant Very Good	Grifols Plant Excellent
Almirall Plant	Almirall Plant Poor	Almirall Plant Fair	Almirall Plant Good	Almirall Plant Very Good	Almirall Plant Excellent
Biomedical Research Park	Biomedical Research Park Poor	Biomedical Research Park Fair	Biomedical Research Park Good	Biomedical Research Park Very Good	Biomedical Research Park Excellent

Page1 / 1

100% of survey complete.

Question Title

* 1. How would you rate your level of satisfaction with this ISPE 2017 Europe Annual Conference in the following areas?

Question Title

* 2. How likely is it that you would recommend the event to a friend or colleague?

Question Title

* 3. Why did you register for this ISPE 2017 Europe Annual Conference? Please tick all boxes that apply.

Question Title

* 4. How did you learn about this ISPE 2017 Europe Annual Conference?

Question Title

* 5. Please evaluate the relevance and presentation of the Keynote speakers

Question Title

* 6. Please evaluate the relevance and presentation of the speakers of Track 1: Factories Of The Future

Question Title

* 7. Please evaluate the relevance and presentation of the speakers of Track 2: Advanced Aseptic Processing

Question Title

* 8. Please evaluate the relevance and presentation of the speakers of Track 3: Clinical and ATMP Supply Chain

Question Title

* 9. Please evaluate the relevance and presentation of the speakers of Track 4: Data Integrity and GAMP®

Question Title

* 10. Please evaluate the relevance and experience of the plant tours

* 5. Please evaluate the relevance and presentation of the
Keynote speakers

* 6. Please evaluate the relevance and presentation of the speakers of
Track 1: Factories Of The Future

* 7. Please evaluate the relevance and presentation of the speakers of
Track 2: Advanced Aseptic Processing

* 8. Please evaluate the relevance and presentation of the speakers of
Track 3: Clinical and ATMP Supply Chain

* 9. Please evaluate the relevance and presentation of the speakers of
Track 4: Data Integrity and GAMP®